Anzeige
Mehr »
Mittwoch, 03.09.2025 - Börsentäglich über 12.000 News
Geheime Uran-Aktie: Ist das der historische "New Deal"-Moment für amerikanischen Uransektor?
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2N951 | ISIN: SE0010133785 | Ticker-Symbol: AC6
Frankfurt
03.09.25 | 11:07
0,354 Euro
+19,59 % +0,058
Branche
Pharma
Aktienmarkt
Sonstige
1-Jahres-Chart
ALZECURE PHARMA AB Chart 1 Jahr
5-Tage-Chart
ALZECURE PHARMA AB 5-Tage-Chart

Aktuelle News zur ALZECURE PHARMA Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
26.08.AlzeCure Pharma: AlzeCure Publishes its Interim Report for January - June 2025223STOCKHOLM, SE / ACCESS Newswire / August 26, 2025 / AlzeCure Pharma AB (publ) (FN STO:ALZCUR) today announced that its interim report for the period January - June 2025 is now available on the company's...
► Artikel lesen
20.08.AlzeCure Pharma: AlzeCure Appoints Cecilia Wadell as New Head of Development263STOCKHOLM, SE / ACCESS Newswire / August 20, 2025 / AlzeCure Pharma AB (publ) (FN STO:ALZCUR), a pharmaceutical company that develops candidate drugs for diseases affecting the nervous system, focusing...
► Artikel lesen
19.08.AlzeCure Pharma Livestreams Event about The Pain Project ACD440 and The Opportunities Within Orphan Drugs254STOCKHOLM, SE / ACCESS Newswire / August 19, 2025 / AlzeCure Pharma AB (publ) (FN STO:ALZCUR), a pharmaceutical company that develops candidate drugs for diseases affecting the nervous system, focusing...
► Artikel lesen
11.08.New last trading day for paid subscription shares (BTA) of AlzeCure Pharma AB176At the request of AlzeCure Pharma AB, the last trading day in AlzeCure Pharma AB's paid subscription shares will be changed from 2025-08-14 to 2025-08-13. Instrument: Paid subscription...
► Artikel lesen
05.08.AlzeCure Pharma: New Scientific Data with TrkA-NAM ACD137 Against Knee Osteoarthritis to be Presented at Pain Conference329STOCKHOLM, SE / ACCESS Newswire / August 5, 2025 / AlzeCure Pharma AB (publ) (FN STO:ALZCUR), a pharmaceutical company that develops candidate drugs for diseases affecting the nervous system, focusing...
► Artikel lesen
ALZECURE PHARMA Aktie jetzt für 0€ handeln
29.07.AlzeCure Pharma: New Scientific Article Published on Positive Clinical Results with Painless ACD440 Against Neuropathic Pain380STOCKHOLM, SE / ACCESS Newswire / July 29, 2025 / AlzeCure Pharma AB (publ) (FN STO:ALZCUR), a pharmaceutical company that develops candidate drugs for diseases affecting the nervous system, focusing...
► Artikel lesen
24.07.AlzeCure Pharma: AlzeCure's Rights Issue Oversubscribed, And the Company Resolves on A Directed Share Issue Under the Framework of An Overallotment Option307THIS PRESS RELEASE MAY NOT BE PUBLISHED OR DISTRIBUTED, DIRECTLY OR INDIRECTLY IN OR INTO AUSTRALIA, HONG KONG, JAPAN, CANADA, NEW ZEALAND, SINGAPORE, SOUTH AFRICA, THE UNITED STATES, BELARUS, RUSSIA...
► Artikel lesen
23.07.AlzeCure Pharma: AlzeCure's Rights Issue Oversubscribed According to Preliminary Results267THIS PRESS RELEASE MAY NOT BE PUBLISHED OR DISTRIBUTED, DIRECTLY OR INDIRECTLY IN OR INTO AUSTRALIA, HONG KONG, JAPAN, CANADA, NEW ZEALAND, SINGAPORE, SOUTH AFRICA, THE UNITED STATES, BELARUS, RUSSIA...
► Artikel lesen
21.07.AlzeCure Pharma: AlzeCure Presents ACD440 at the NeuPSIG 2025 Pain Conference284STOCKHOLM, SE / ACCESS Newswire / July 21, 2025 / AlzeCure Pharma AB (publ) (FN STO:ALZCUR), a pharmaceutical company that develops candidate drugs for diseases affecting the nervous system, focusing...
► Artikel lesen
16.07.FDA grants orphan status for AlzeCure's pain drug candidate3
16.07.AlzeCure Pharma: AlzeCure Receives Additional Subscription Commitments of Approximately SEK 7 million in the Ongoing Rights Issue265NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, WITHIN OR INTO THE AUSTRALIA, HONGKONG, JAPAN, CANADA, NEW ZEALAND, SINGAPORE, SOUTH AFRICA, THE UNITED STATES...
► Artikel lesen
15.07.AlzeCure Pharma: AlzeCure's Pain Project ACD440 Granted Orphan Drug Status in the US by the FDA313STOCKHOLM, SE / ACCESS Newswire / July 15, 2025 / AlzeCure Pharma (STO:ALZCUR) (FRA:AC6) AlzeCure Pharma AB (publ) (FN STO:ALZCUR), a pharmaceutical company that develops candidate drugs for diseases...
► Artikel lesen
02.07.The Extraordinary General Meeting of AlzeCure Pharma AB Approved the Decision on the New Issue of Shares323STOCKHOLM, SE / ACCESS Newswire / July 2, 2025 / AlzeCure Pharma (STO:ALZCUR)(FRA:AC6) - At an extraordinary general meeting in AlzeCure Pharma AB on July 2, 2025, the shareholders decided to approve...
► Artikel lesen
02.07.XFRA CAPITAL ADJUSTMENT INFORMATION - 02.07.2025275Das Instrument 3MM FR0013296746 ADVICENNE (PROM.) EO-,20 EQUITY wird ex Kapitalmassnahme gehandelt am 02.07.2025 The instrument 3MM FR0013296746 ADVICENNE (PROM.) EO-,20 EQUITY is traded ex capital...
► Artikel lesen
17.06.AlzeCure Pharma: AlzeCure Receives an Additional Subscription Commitment of Approximately SEK 5 million in the Upcoming Rights Issue338NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, WITHIN OR INTO THE RUSSIAN FEDERATION, BELARUS, AUSTRALIA, HONGKONG, JAPAN, CANADA, NEW ZEALAND, SWITZERLAND...
► Artikel lesen
16.06.Notice To Extraordinary General Meeting In Alzecure Pharma AB321STOCKHOLM, SE / ACCESS Newswire / June 16, 2025 / AlzeCure Pharma (STO:ALZCUR)(FRA:AC6) - The shareholders of AlzeCure Pharma AB are hereby summoned to an extraordinary general meeting to be held on...
► Artikel lesen
16.06.AlzeCure Pharma: AlzeCure Carries out a Rights Issue of Approximately SEK 48.5 million398NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, WITHIN OR INTO THE RUSSIAN FEDERATION, BELARUS, AUSTRALIA, HONGKONG, JAPAN, CANADA, NEW ZEALAND, SWITZERLAND...
► Artikel lesen
12.06.AlzeCure Pharma: AlzeCure receives positive FDA response regarding Phase II/III studies with ACD440 in a rare disease405STOCKHOLM, SE / ACCESS Newswire / June 12, 2025 / AlzeCure Pharma (STO:ALZCUR)(FRA:AC6) - AlzeCure Pharma AB (publ) (FN STO:ALZCUR), a pharmaceutical company that develops candidate drugs for diseases...
► Artikel lesen
04.06.AlzeCure Pharma to present at Redeye Investor Forum on June 11313STOCKHOLM, SE / ACCESS Newswire / June 4, 2025 / AlzeCure Pharma (STO:ALZCUR)(FRA:AC6) - AlzeCure Pharma AB (publ) (FN STO: ALZCUR), a pharmaceutical company that develops candidate drugs for diseases...
► Artikel lesen
03.06.AlzeCure Pharma to Present at Stora Aktiedagarna in Stockholm on June 10362STOCKHOLM, SE / ACCESS Newswire / June 3, 2025 / AlzeCure Pharma AB (publ) (FN STO:ALZCUR), a pharmaceutical company that develops candidate drugs for diseases affecting the nervous system, focusing...
► Artikel lesen
Weiter >>
42 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1